A database system of cardiovascular drugs with potential anti-tumor properties （CDPAP）
Project
name：A database system of cardiovascular drugs with potential anti-tumor properties （CDPAP）
BuildTime：2024-06-27
Mark
In recent years, More and more researches have indicated the significant role of cardiovascular drugs in anti-tumor therapy. To gain a deeper understanding of the potential mechanisms in this field and explore novel therapeutic avenues, we have established a Cardiovascular Drugs in Anti-Tumor Database. This database comprises a total of 108 cardiovascular drugs targeting 79 therapeutic markers, applicable for the treatment of various cancers such as gastric cancer, colorectal cancer, breast cancer, lung cancer, pancreatic cancer, cervical cancer, and others. The drugs are primarily categorized into angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, diuretics, beta-blockers, ion channel blockers, anticoagulants, etc. These drugs exert inhibitory effects on cancer by mediating signaling pathways and interacting with target proteins, leading to the blockade of the cell cycle or induction of apoptosis. Through a systematic analysis of drug repurposing, we have identified numerous drugs with potential anti-tumor effects. The establishment of this database provides a theoretical foundation for the application of cardiovascular drugs in anti-tumor treatment. By delving into the anti-tumor mechanisms of these drugs, we hope to find new drug targets, offering robust support for the future repurposing of cardiovascular drugs. This research holds crucial guidance for enhancing drug development efficiency.
